Tokio Marine Asset Management Co. Ltd. Has $1.07 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Tokio Marine Asset Management Co. Ltd. lowered its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,049 shares of the medical research company’s stock after selling 616 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Edwards Lifesciences were worth $1,071,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Edwards Lifesciences by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company’s stock valued at $3,577,163,000 after purchasing an additional 325,808 shares in the last quarter. Wellington Management Group LLP raised its position in Edwards Lifesciences by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock valued at $1,138,575,000 after purchasing an additional 1,390,427 shares during the last quarter. Brown Advisory Inc. increased its stake in Edwards Lifesciences by 5.7% in the 3rd quarter. Brown Advisory Inc. now owns 15,133,146 shares of the medical research company’s stock valued at $1,048,424,000 after buying an additional 818,849 shares during the period. Northern Trust Corp lifted its holdings in shares of Edwards Lifesciences by 3.9% in the third quarter. Northern Trust Corp now owns 6,357,473 shares of the medical research company’s stock valued at $440,446,000 after purchasing an additional 241,347 shares in the last quarter. Finally, WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST increased its position in Edwards Lifesciences by 16.8% during the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,100,000 shares of the medical research company’s stock worth $312,625,000 after purchasing an additional 590,000 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Edwards Lifesciences news, VP Catherine M. Szyman sold 27,000 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the sale, the vice president now owns 34,814 shares in the company, valued at $2,980,774.68. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 194,004 shares of company stock valued at $17,166,254. 1.29% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have commented on EW. Stifel Nicolaus boosted their target price on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the stock a “hold” rating in a research report on Wednesday, February 7th. Oppenheimer lifted their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Citigroup upped their price target on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. Mizuho upped their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Finally, Wells Fargo & Company raised shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective on the stock in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $91.73.

Edwards Lifesciences Trading Down 2.2 %

EW traded down $1.92 during midday trading on Friday, reaching $86.09. 1,359,385 shares of the company were exchanged, compared to its average volume of 3,796,061. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The stock has a market capitalization of $51.82 billion, a P/E ratio of 37.43, a PEG ratio of 4.39 and a beta of 1.05. The stock’s 50-day simple moving average is $90.27 and its 200 day simple moving average is $78.76.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. As a group, analysts forecast that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.